The COVID-19 pandemic has resulted in a 46% decline in identifying new cancer diagnoses in the US, causing delayed delivery of treatment. Urgent action is needed to avoid a potential increase in cancer deaths due to delayed diagnoses.1
While every health system has its own approach to handling the return to preventive and elective patient care during the COVID-19 pandemic, rest assured we are prepared to continue to support your organization, physicians, and patients in whatever capacity you may need.
Quest can provide insights that help lab managers, pathologists, and clinicians collaborate to drive targeted enhancements in test selection and interpretation, and improvements in lab operations and patient outcomes.
Our experts can review your lab operations and help implement changes to increase lab efficiency and productivity, helping you manage post-COVID test volumes. Opportunities for efficiency include increasing process standardization, moving high-cost testing off-site, balancing staffing with volume and workflow, and more.
New research shows that the number of positive HCV RNA diagnostic test results and medication prescriptions in July 2020 declined 40%, compared to same month of 2018/2019, attributed to patients not accessing healthcare services for potentially life-saving treatment and care during the early months of the pandemic.
1 Kaufman HW, Chen Z, Niles J, et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267. doi:10.1001/jamanetworkopen.2020.172677
2 Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-1830. doi:10.1001/jama.2021.5469
3 Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul Health Manag. 2021;24(S1):S43-S51.
4 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
5 Kaufman HW, Bull-Otterson L, Meyer III WA, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med. Epub May 10, 2021. Accessed August 6, 2021. doi:10.1016/j.amepre.2021.03.011
6 Manohar P, Loh B, Athira S, et al. Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics? Front Microbiol. 2020;11:1434. doi: 10.3389/fmicb.2020.01434
7 Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5
• The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
• The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
• The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
• The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
• The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
• The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.
• The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
• The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
As you work to keep up with ongoing COVID-19 care, catching up on deferred care creates further pressure on clinical staff.